The results are of interest because they show location- and gender-specific differences in Wnt-11 protein levels in colorectal cancer and because they suggest that antibody-mediated inhibition of Wnt-11 should be considered as a possible approach for future therapies for metastatic CRC. This evidence concerns the gene WNT11 and colorectal cancer.